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A
 
BSTRACT
 
In a recent epidemiological study, 15–20% of the pop-
ulation in Japan was estimated to have allergic con-
junctivitis. Allergic conjunctival diseases (ACD) have a
wide spectrum of clinical severity and the treatment
strategy depends on the severity and duration of the
disease. Most cases of the non-proliferative type of
ACD, such as seasonal or perennial allergic conjuncti-
vitis, can be treated with topical anti-allergic drugs. Of
the ACD, vernal keratoconjunctivitis (VKC) is charac-
terized by typical proliferative lesions, such as giant
papillae and severe corneal lesions. Corticosteroid eye
drops should be used in combination with anti-allergic
eye drops when an anti-allergic drug is insufficient
in cases of VKC and atopic keratoconjunctivitis with
proliferative lesions. In spite of the high effectiveness
of corticosteroid eye drops, they have important
side-effects, such as elevation of intraocular pressure
leading to glaucoma. Immunosuppressive agents and
non-steroidal anti-inflammatory drugs (NSAIDs) are
alternative topical agents to corticosteroids. Topically
administered immunosuppressive agents, such as
ciclosporin and tacrolimus, have antifibroblastic actions
by inhibiting remodeling-inducing cells and act as a
controller in the treatment of ACD. Non-steroidal anti-
inflammatory drug eye drops can be used to inhibit
remodeling in ACD because of their excellent anti-
inflammatory and antifibroblastic effects, next to
corticosteroids and immunosuppressive agents. Sub-
stitution of the topical treatment with corticosteroids
by these agents in ACD not only spares the use of
corticosteroids and decreases the risk of side-effects,
but also brings about a more favorable effect in the
long-term control of proliferative-type ACD.
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NTRODUCTION
 
A previous report indicated that 12.2% of children and
14.8% of adults have a past history of allergic conjunc-
tivitis diagnosed by a physician.
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 Therefore, it is esti-
mated that 15–20% of the population in Japan has
allergic conjunctivitis.
 
2
 
 Allergic conjunctival diseases
(ACD) are one of the most common types of disease
seen in ophthalmologic out-patient clinics in Japan and
developed countries. The ACD have a wide spectrum of
clinical severity and the treatment strategy depends on
the severity and duration of the disease. The patho-
genesis of these diseases shows an important correlation
with systemic allergic diseases, especially atopic derma-
titis (AD), which has been increasing in Japan recently,
and some types of ACD may also bring about serious
visual impairment. The most widely used and basic
treatment agents are anti-allergic eye drops, such as
disodium cromoglycate (DSCG) and tranilast, which are
also called mast cell stabilizers. Corticosteroids have
also been considered as the most useful and effective
drugs when given locally as eye drops for patients with
ACD. However, they have serious side-effects, such as
elevation of intraocular pressure (IOP), even with topical
instillation as eye drops. We hereafter describe the
current therapeutic strategies for ACD according to
the severity of the disease and discuss the possibility of
non-steroidal treatment in ACD based on recent progress
in clinical and immunological studies on ocular allergy.
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CLINICAL FEATURES AND STANDARD OF 
TREATMENT OF ACD
The Allergic Ocular Diseases Study Group supported by
the Japanese Society of Clinical Ophthalmologists has
previously proposed definitions and classification of
allergic conjunctival diseases, namely, allergic con-
junctivitis, atopic keratoconjunctivitis (AKC), vernal
keratoconjunctivitis (VKC) and giant papillary con-
junctivitis (GPC).2 The former two diseases are non-
proliferative and the latter two have proliferative lesions.
Patients with AKC have AD and conjunctival and/or
corneal involvement. The corneal and conjunctival lesions
in AKC are non-proliferative, showing conjunctival papil-
lae, especially on the upper tarsal conjunctiva (Fig. 1), or
superficial punctate keratopathy, in contrast with that in
VKC, which exhibits proliferative lesions such as giant
papillae or corneal plaques.3 The major symptoms of
allergic ocular disease are itching, tearing and foreign
body sensation, but, in contrast with viral conjunctivitis,
ocular discharge is rare. Dry eye caused by a decrease of
conjunctival goblet cells is sometimes seen in ocular
allergy. Follicles and papillae are the most typical find-
ings in the conjunctiva. Superficial punctate keratitis is
found in some cases. Giant papillary conjunctivitis, in
which giant papillae >1.0 mm in size are found, is
caused by extended wearing of soft contact lenses, stimu-
lation by ocular prostheses or surgical sutures in the
upper tarsal conjunctiva.
Vernal keratoconjunctivitis is diagnosed by slit lamp
examination showing typical cobblestone excrescences
(giant papillary conjunctivitis of the upper palpebral con-
junctiva >1 mm in size; Fig. 2), perilimbal gelatinous
change and severe corneal lesions, such as plaques or
ulcers (Fig. 3). These patients have very severe clinical
symptoms, more marked than those in allergic conjuncti-
vitis, including positivity for serum antigen-specific IgE.
Vernal keratoconjunctivitis is often seen in young men
with a history of AD.4 It has been reported that cellular
immunologic reactions play an important role in the
development of the severe ocular lesions that are often
found in patients with VKC.
Results of recent studies indicate a predominance of
T helper (Th) 2 activity in ocular allergy.5 The serum level
of IgE is significantly increased in AD patients with ocular
complications compared with AD patients without ocular
complications, and the positive rates of IgE-RAST (radio-
allergosorbent assay) for rice and wheat are significantly
higher in ocular-type AD than in non-ocular-type AD.6
Fig. 1 Conjunctival lesion of atopic keratoconjunctivitis. Slight
conjunctival hyperemia and pigmentation are observed.
Fig. 2 Conjunctival finding of vernal keratoconjunctivitis.
Typical cobblestone excrescences are shown in a patient with
atopic dermatitis.
Fig. 3 Corneal involvement of vernal keratoconjunctivitis. A
corneal ulcer complicated by a corneal plaque is shown.
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These results suggest that ocular-type AD belongs to the
most severe end of the spectrum of AD and that some
food antigens may contribute to the pathogenesis of
severe AD resulting in ocular complications.
Most cases of allergic conjunctivitis can be controlled
by local (eye drops) anti-allergic drugs (Table 1). Corti-
costeroid eye drops should be used in combination with
anti-allergic eye drops only when an anti-allergic drug is
insufficient. Anti-allergic eye drops are divided into two
types: (i) those that act solely as an inhibitor of chemical
mediator release (pemirolast potassium, cromoglycate
sodium, tranilast and amlexanox); and (ii) those that
inhibit the release of both chemical mediators and hista-
mine (ketotifen fumarate).
Anti-allergic eye drops are used in recurrent cases of
pollen-induced conjunctivitis as a prophylactic treatment
2 weeks prior to the pollen season. Immunotherapy is the
sole etiotropic treatment for ocular allergy and may be
tried for juvenile cases in which the causative allergens
are known.
Emedastine and azelastine (chemical mediator inhibi-
tor and histamine antagonist), levocabastine (specific
histamine H
 
1
 
 receptor antagonist), apafant (inhibitor of
platelet-activating factor) and ciclosporin (immuno-
suppressive agent) are under clinical trial for ACD in
Japan. An inhibitor of cytokine synthesis (suplatast
tosilate
 
7
 
), an inhibitor of thromboxane (TX) A
 
2
 
 synthe-
sis (ozagrel sodium
 
8
 
), a TXA
 
2
 
 receptor antagonist
(seratrodast
 
9
 
) and a leukotriene receptor antagonist
(pranlukast
 
10
 
) are under investigation as ocular topical
treatments. In the near future, more types of eye drop
drugs will be available for ACD, including the above-
mentioned agents.
In contrast, however, the above-mentioned therapeu-
tic measures are often ineffective in VKC with proliferative
lesions. Corticosteroid eye drops are necessary to treat
these patients, because allergic proliferative lesions, such
as giant papillae and limbal infiltrative changes, are con-
sidered to represent tissue remodeling due to recurrent
epithelial inflammation and imperfect tissue repair.
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 For
the long-term control of allergic inflammation including
ACD, topical instillation of corticosteroids is essential.
However, corticosteroids have several unwanted effects,
as described later, and the lack of effective treatment to
spare the use of corticosteroids has been considered an
important clinical problem.
Removal of causative foreign bodies, such as contact
lenses, ocular prostheses or surgical sutures, should be
the primary treatment in GPC. If contact lens wear cannot
be stopped, a gas-permeable lens or non-ionic low-
hydrous soft lens should be used. In these cases, anti-
allergic drugs may be given topically, but corticosteroid
eye drops should not be used. Because parasites may,
rarely, cause GPC, close observation of the tarsal con-
junctiva is necessary when an ordinary causative material
is not found. Cleaning of the skin with 50% baby
shampoo and moistening with white petrolatum is effec-
tive for eczematous eyelid involvement in AD patients.
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UBSTITUTIONAL
 
 
 
TREATMENT
 
 
 
MEASURES
 
 
 
TO
 
 
 
SPARE
 
 
 
THE
 
 
 
USE
 
 
 
OF
 
 
 
CORTICOSTEROIDS
 
In spite of the high effectiveness of corticosteroid eye
drops in the treatment of ACD, they have important side-
effects, such as elevation of IOP leading to steroidal
glaucoma, induction of infectious keratitis or conjunctivi-
tis and prolonged epithelial defect. The most important
and serious side-effect is ocular hypertension, which is
thought to be genetically determined,
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 and such
patients are termed ‘steroid responders’. The use of
topical corticosteroids is contraindicated in these
patients and if they have proliferative ocular lesions in
 
Table 1
 
Pharmacological features of anti-allergic eye drops
Drugs Histamine antagonist Stabilization of 
mast cells
Specific feature Other characteristic
Cromoglycate sodium –
 

 
Tranilast –
 

 
TGF
 
β
 
 antagonist
Amlexanox –
 

 
Ibudilast –
 

 
Tazanolast –
 

 
Pemirolast potassium –
 

 
Twice a day instillation
Ketotifen fumarate
 
 
 
Levocabastine
 

 
– Specific histamine H
 
1
 
 
receptor antagonist
 
TGF
 
β
 
, Transforming growth factor 
 
β
 
.
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VKC or AKC, treatment without corticosteroids is very
difficult. To decrease the topical use of corticosteroids,
there are several alternative routes for corticosteroids as
follows. Frequent instillation or subconjunctival injection
of corticosteroid with 1.0% lidocaine hydrochloride may
be effective for corneal complications and giant papillae
in VKC. Sub-bulbar conjunctival water-soluble steroid
may be injected for the treatment of limbal proliferative
lesions of VKC. Triamcinolone acetonide, which diffuses
slowly into tissue, is also widely used clinically for long-
term control in patients with VKC. Oral administration of
prednisolone or methyl prednisolone at 5–20 mg every
other day may be effective for serious cases, because
these drugs have a short half-life in the blood. Pro-
longed systemic administration of corticosteroids with a
long half-life, such as betamethasone and dexametha-
sone, may cause suppression of adrenocortical function
or inhibition of methaphyseal growth. These routes of
systemic or local administration of corticosteroids are
effective and decrease the risk of IOP elevation and
other side-effects specific to corticosteroid eye drops.
Other types of drugs can be used topically to support
or substitute for corticosteroids, namely immunosuppres-
sive agents and non-steroidal anti-inflammatory drugs
(NSAIDs). The immunosuppressive agents ciclosporin
and tacrolimus are under clinical trial in Japan for the
treatment of VKC and chronic-type ACD. Ciclosporin eye
drops are reported to have a similar effect to cortico-
steroids on proliferative lesions in VKC.
 
13
 
 The mechanism
of action of ciclosporin in the treatment of VKC is not only
suppression of cellular immunity, but also a suppressive
effect on non-immunological cells, such as vascular
endothelial cells, corneal stromal cells and fibroblasts.
 
14
 
Based on their pharmacological properties, immunosup-
pressive agents lack an immediate effect and anti-allergic
activity and have less anti-inflammatory activity com-
pared with corticosteroids, but have a sufficient anti-
fibroblastic action by inhibiting remodeling-inducing
cells, such as vascular endothelial cells, fibroblasts and
mast cells. Thus, topically administered immunosuppres-
sive agents act as controllers in the treatment of ACD.
Non-steroidal anti-inflammatory drug eye drops have
been recognized recently as one of the treatment meas-
ures in ACD, with a similar effect to that of anti-allergic
eye drops (Table 2).
 
15–17
 
 Of the NSAIDs, pranoprofen,
diclofenac sodium and bromfenac sodium are currently
commercially available as eye drops in Japan. Although
ketorolac is widely used in patients with ACD in Europe
and has been shown to have satisfactory efficacy,
 
17
 
 it is
not authorized for topical use in Japan. Non-steroidal
anti-inflammatory drugs decrease hyper-reactivity of
inflammatory cells, such as mast cells and lymphocytes,
during re-epithelialization after keratoconjunctival inflam-
mation and lead to suppression of fibroblastic and vascu-
lar endothelial cell activity, as well as having anti-allergic
activity comparable with that of anti-allergic eye
drops.
 
18,19
 
 Therefore, NSAID eye drops can be used a
controller against remodeling in ACD owing to their
excellent anti-inflammatory and antifibroblastic effects,
next to corticosteroids and immunosuppressive agents.
Based on these interesting pharmacological features of
NSAIDs in the topical treatment of ACD, combined long-
term local application of NSAID eye drops with cortico-
steroid and anti-allergic eye drops has potential in the
treatment and control of VKC. However, NSAID eye
drops may induce corneal complications and sometimes
induce anaphylactic reactions owing to their aspirin-like
properties. Non-steroidal anti-inflammatory drug eye
drop-induced asthma attacks have been reported in
patients with aspirin sensitivity.
 
20,21
 
 The NSAID eye drops
should not be given to patients with asthma and aspirin
sensitivity unless the patient is known to tolerate NSAIDs
without trouble.
 
C
 
ONCLUSIONS
 
Immunologic and allergologic mechanisms are involved
in the development of ocular allergic diseases and they
have an important relationship with the treatment of
ACD. Substitutional topical treatment measures for
ACD to corticosteroids by immunosuppressive agents
and NSAIDs not only spare the use of corticosteroids
and decrease the risk of IOP elevation, but also bring
about a more favorable effect in the long-term inhibition
of proliferative lesions in VKC. Clinical and basic research
in ocular allergy is expected to develop drugs that can be
used more safely and efficiently for such patients and
improve the quality of life of patients with ACD.
 
Table 2
 
Non-steroidal anti-inflammatory drug eye drops for
allergic conjunctival diseases
Drugs Specific characteristics
Pranoprofen
Diclofenac sodium
Bromfenac sodium Twice a day instillation
Indomethacin 0.5% oily solution
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